In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Pfizer released positive top line results from the final prespecified overall survival (OS) analysis of the TALAPRO-2 study of Talzenna (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with Xtandi (enzalutamide). 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
Cancer start-up Black Diamond Therapeutics has announced a significant restructuring as part of its plan to focus resources on its lead drug, BDTX-1535. 10 October 2024
The European Medicines Agency (EMA) has accepted for review the Marketing Authorization Applications for AVT03, a proposed biosimilar candidate to the Prolia and Xgeva (denosumab), submitted by Germany’s STADA Arzneimittel. 10 October 2024
China’s Quantum Pharmaceuticals has announced a significant licensing agreement between its biologics-focused subsidiary, Ailux Biologics, and Johnson & Johnson. 10 October 2024
Advances in gene editing, such as the FDA approval of Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) in December 2023 for the treatment of beta thalassemia and sickle cell disease, have fueled significant interest in innovative epigenetic drugs. 10 October 2024
German family-owned pharma major Boehringer Ingelheim and USA-based Circle Pharma (have entered into a research collaboration and license agreement with the shared goal to develop a first-in-class cyclin inhibitor that can halt the growth of cancer cells potentially offering hope to those living with hard-to-treat cancers. 9 October 2024
Bayer has entered into a collaboration with MOMA Therapeutics to develop a small molecule oncology program using the latter’s proprietary KNOMATIC platform. 9 October 2024
Genor Biopharma has announced plans for a significant merger with Edding Group, marking one of the first reverse takeovers involving a Hong Kong-listed biopharma company. 8 October 2024
China-headquartered clinical-stage biotech MediLink Therapeutics has announced a global clinical trial collaboration and supply agreement with US major Amgen. 8 October 2024
Germany’s Eckert & Ziegler, a specialist in radioisotopes for medical, scientific and industrial applications, has announced a global clinical supply agreement with GlyTherix, an Australian targeted radiotherapy firm specializing in developing antibody radiopharmaceuticals for solid tumors. 8 October 2024
US clinical-stage biotech OnKure Therapeutics has announced the completion of its previously announced merger with Reneo Pharmaceuticals. 8 October 2024
Daejeon-based Orum Therapeutics, a specialist in degrader-antibody conjugates (DAC), has filed for an initial public offering (IPO) on South Korea's Kosdaq market. 7 October 2024
Mosaic Therapeutics, a UK-based oncology therapeutics company dedicated to resolving cancer’s complexity to power new combination therapies for patients, has announced the appointment of Barry Davies as chief scientific officer. 7 October 2024
The US Food and Drug Administration on Friday granted accelerated approval for pharma giant Merck & Co’s Keytruda (pembrolizumab) in a new indication. 3 October 2015
A pressure group has called on the UK’s Health Secretary Jeremy Hunt to grant a compulsory license for patents that cover Kadcyla (trastuzumab emtansine) from Roche. 2 October 2015
Berg, the Boston-based biopharma company specializing in precision medicine, is to join forces with Genomics England in the project to sequence 100,000 human genomes and create a new genomic medicine service for the UK by 2017. 2 October 2015
Jordon-headquartered Hikma Pharmaceuticals has agreed to acquire 98.09% of the share capital of Egyptian drugmaker EIMC United Pharmaceuticals (EUP) from a consortium of shareholders. 2 October 2015
German pharma company Merck issued an update on its pipeline, primarily that it has begun investigating a novel, potential first-in-class bi-functional immunotherapy that would be an alternative to anti-PD-1/anti-PD-L1 therapies. 1 October 2015
The US Food and Drug Administration today approved US pharma major Bristol-Myers Squibb’s Opdivo (nivolumab) in combination with Yervoy (ipilimumab), for the treatment of patients with BRAF V600 wild-type unresectable or metastatic melanoma. 1 October 2015
"Prolonging life is the gold standard endpoint of any drug trial," Professor John Crown, consultant medical oncologist for St Vincent’s University Hospital told The Pharma Letter in an interview, as the Japanese pharmaceutical giant Eisai announced data for its clinical trials at the European Cancer Congress in Vienna. 30 September 2015
Privately held US clinical stage immuno-oncology company UbiVac has entered into a collaboration with Janssen Biotech, a subsidiary of US health care giant Johnson & Johnson. 29 September 2015
US privately-held industry pioneer in gene control Syros Pharmaceuticals has entered into an exclusive license agreement with the Japanese oncology company TMRC Co, to develop and commercialize tamibarotene in North America and Europe for cancer. 29 September 2015
Swiss drug major Roche on Monday said late stage trials for its drug to treat primary progressive multiple sclerosis met its primary endpoint. 28 September 2015
Clinical-stage US biotech firm Sorrento Therapeutics has formed a new company, named LA Cell, to focus on the development of groundbreaking cell-penetrating antibody therapies. 28 September 2015
French molecular nuclear medicines specialist Advanced Accelerator Applications SA (AAA) said late stage trials for its drug to treat a rare form of cancerous tumors met its primary end point of assessing progression-free survival (PFS). 28 September 2015
Aspirin improves survival in patients with tumors situated throughout the gastrointestinal (GI) tract, results from a large study in the Netherlands show, reports EurekAlert. 28 September 2015
US drugmaker Exelixis said late stage trial for Cometriq (cabozantinib) versus Swiss drug major Novartis' Afinitor (everolimus) in some patients with kidney cancer showed median progression-free survival (PFS) of 7.4 months. 28 September 2015
Swiss drug major Novartis said Phase III combination study for skin cancer has shown a significant overall survival benefit for patients. 28 September 2015
US drug major Bristol-Myers Squibb has said late stage trials for its drug candidate to treat a form of kidney cancer improved overall survival. 28 September 2015
Merck KGaA and Pfizer have partnered with Dako to develop avelumab, a trial stage immunology compound to treat various kinds of cancers. 26 September 2015
The European Medicines Agency has recommended granting a marketing authorisation for Kyprolis (carfilzomib) to treat patients with multiple myeloma whose disease has relapsed. 25 September 2015
Swiss pharma giant Roche said today that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Cotellic (cobimetinib), when used in combination with Zelboraf (vemurafenib), for the treatment of BRAF V600 mutation-positive unresectable or metastatic melanoma. 25 September 2015